SNC take from NAV release today.Cheers,xmagxIDT released a one...

SNC take from NAV release today.

Cheers,
xmagx

IDT released a one sentence announcement that put a rocket under the share price (+140% for the month), disclosing that it had been requested by the Australian Government’s Department of Health to undertake “a feasibility assessment to assess the possibility of utilising the Company’s sterile manufacturing facility to supplement the production capability for a COVID-19 vaccine.” Whilst the company has not yet disclosed which vaccine it may be asked to produce, we do note that IDT’s capabilities are wide ranging. In a release to the ASX in August 2020, IDT disclosed that its current and potential COVID-19 vaccine and treatment capabilities included:

 Sterile vial fill/finish of liquid and lyophilised products;
 Bulk liquid formulation;
 Cold chain management and storage (cGMP);
 Solid oral dose form manufacture (tablet/capsule);
 Manufacture of Active Pharmaceutical Ingredients (APIs) and excipients;
 Process and analytical method development; and
 In-house analytical and microbiological testing

Given the difficulties that have so far been encountered with the vaccine roll out in Australia, we eagerly await future updates from IDT on how it might assist the Government in its vaccination effort.